Key facts
- Notable investors include Buenavista Equity Partners, Asahi Kasei Corporate Venture Capital, Asahi Kasei Medical, Columbus Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Syngoi
- ·The full record, as it builds
Funding rounds
No funding rounds for Syngoi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syngoi
Producer of synthetic deoxyribonucleic acid intended to address the needs of advanced therapies. The company is engaged in the production of synthetic DNA through a new enzymatic process that addresses the needs of advanced therapies, where it is the fundamental starting material, and this process allows manufacturing under conditions, are cost-effective, high-fidelity, significantly faster than production, and customizable, enabling biotech companies to develop and commercialize therapeutic strategies in advanced therapies.
- Sector
- Healthcare
- HQ
- Bilbao, Spain
- Founded
- 2021
- Employees
- 38
- Website
- syngoi.com/
- Ownership
- Privately Held (backing)
Syngoi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syngoi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syngoi in its N-PORT filings yet. We sweep new filings monthly.